In 8/8 HLA-matched unrelated donor (UD) hematopoietic cell transplants (HCT), HLA-DPB1 mismatches between alleles from different T-cell epitope (TCE) groups (non-permissive mismatches) are associated with significantly higher risks of mortality compared with those between alleles from the same TCE group (permissive mismatches); however, the relevance of mismatch directionality, that is (host vs graft (uni-directional HvG), graft vs host (uni-directional GvH) or both (bi-directional) in the nonpermissive setting is unknown. We show here significantly higher in vitro relative responses (RR) to bi-directional mismatches compared with uni-directional HvG or GvH mismatches in a total of 420 one-way mixed lymphocyte reactions between 10/10 matched pairs (RR 27.5 vs 7.5 vs 15.5, respectively, Po 0.001). However, in 3281 8/8 matched UD HCT for leukemia or myelodysplastic syndrome, the hazards of transplant-related mortality (TRM) were similar for uni-directional HvG or GvH mismatches and bi-directional mismatches (hazard ratio (HR) 1.32, P = 0.001 vs HR 1.28, P = 0.005 and HR 1.34, P = 0.046), compared with permissive mismatches. Similar results were observed for overall survival. No statistical differences between the uni-and the bi-directional non-permissive groups were detected in pairwise comparisons for any of the outcomes tested. We conclude that consideration of directionality does not improve risk stratification by non-permissive HLA-DPB1 TCE mismatches in UD searches.
INTRODUCTION
It is well established that the degree of recipient-donor matching for polymorphic human leukocyte antigen (HLA) molecules is significantly associated with the risk of adverse events after allogeneic hematopoietic cell transplantation (HCT). [1] [2] [3] In contrast, the importance of mismatch directionality is a matter of debate, and few studies have specifically addressed this issue. In particular, it is unclear whether bi-directional mismatches, that is, mismatches in both the host vs graft (HvG) and the graft vs host (GvH) vector have a greater impact on clinical outcomes than uni-directional HvG or GvH mismatches. A recent study from the Center of International Bone Marrow Transplant Research (CIBMTR) found that after HCT from unrelated donors (UD) with a single mismatch at HLA-A,B,C,DRB1 (7/8), mortality risk associations did not differ between uni-or bi-directional mismatches. 4 However, uni-directional HvG mismatches were associated with lower risks of severe acute GvHD compared with uni-directional GvH and bi-directional mismatches. The question of directionality has also been addressed in unrelated umbilical cord blood (UCB) transplants with discordant results. One study showed improved outcomes in terms of engraftment, mortality and treatment failure associated with uni-directional GvH mismatches compared with uni-directional HvG or bi-directional mismatches, 5 while no differences between uni-and bidirectionally mismatched UCB HCT were observed in a different report. 6 Directionality also plays a potential role in the setting of non-permissive T-cell epitope (TCE) group mismatches for HLA-DPB1, which were shown to be associated with the risks of mortality after UD HCT. [7] [8] [9] [10] This model is based on the observation that HLA-DPB1 alleles can be assigned to TCE groups by alloreactive cross-reactivity patterns 7, 11 or by the median impact of amino acid polymorphism on T-cell alloreactivity. 12 HLA-DPB1 mismatches between alleles from different TCE groups (non-permissive TCE mismatches) elicit stronger alloreactive T-cell responses in vitro 13 and are associated with increased risks of adverse clinical outcome [8] [9] [10] than those between alleles from the same TCE group (permissive TCE mismatches). The TCE matching algorithm has recently been incorporated in unrelated donor search tools provided to clinicians by Stem Cell Donor Registries in the United States (HapLogic; https://bethematch.org) and Germany (Optimatch; www.zkrd.de), 14, 15 and is also freely available through the IMGT/HLA database (www.ebi.ac.uk/ipd/imgt/hla). Non-permissive TCE mismatches in GvH or HvG direction have been consistently found to be associated with similar hazards of acute GvHD and mortality in independent studies. 9,10 A possible explanation for this finding could be alloreactivity mediated by residual patient T cells against donor antigen presenting cells in the presence of a non-permissive HvG mismatch. This in turn raises the possibility that in bi-directional non-permissive TCE mismatches, the concomitant presence of a GvH and an HvG mismatch might have an additive effect and thus be associated with the highest clinical risks. The present study was undertaken to test these hypotheses both by in vitro T-cell proliferation assays and by in vivo clinical risk associations after UD HCT.
MATERIALS AND METHODS MLR
One-way MLR was performed at the Leiden University Medical Center (LUMC) as part of the clinical routine, according to standardized protocols accredited by the European Federation for Immunogenetics (EFI), and as previously described. 17 Briefly, peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient from responders (R) and stimulators (S), and 10 5 R-PBMC were subsequently incubated with irradiated (30 Gy) S-PBMC in V-shaped microtiter trays for a total of 120 h, in standard RPMI medium supplemented with 15% human serum. Sixteen hours before harvesting, the cultures were labeled with 1μCi of [R-PBMC] , where the reference value was the median response to stimulation by fully allogeneic unrelated controls. The tests were defined as negative when the RR value was equal to or lower than 10%. Independent MLRs were set up for each pair in both directions, i.e. using patient PBMC as stimulators and donor PBMC as responders, or vice versa. Sample size for the MLR was 420. All experiments were performed in biological triplicates, that is, three independent MLR cultures.
Data source
The clinical data from this study were collected through the CIBMTR (www.cibmtr.org) and the study approved by the National Marrow Donor Program Institutional Review Board, in compliance with all applicable federal regulations pertaining to the protection of human research participants, including informed consent according to the Declaration of Helsinki.
Study population
The MLR study population consisted of 420 unrelated donor-recipient pairs matched at 2nd field for HLA-A,B,C,DRB1,DQB1 (10/10 allele matched) and screened for stem cell transplantation at the Leiden University Medical Center between 1995 and 1999. 2nd field resolution HLA class II DRB1, DQB1, DPB1 typing was performed for all pairs by sequence specific oligonucleotide probing (SSOP), sequence specific priming (SSP) and/or sequence based typing (SBT). The same methods were used for 2nd field resolution HLA class I A, B, C typing for~75% of the pairs, and by serological or 1st field molecular techniques for the remaining pairs.
The clinical outcome study population was part of the cohort already described in Pidala et al. 10 and included 3281 patients who received a first bone marrow (BM) or peripheral blood (PB) unrelated donor stem cell transplantation between 1999 and 2011, for the treatment of AML, ALL or myelodysplastic syndrome (MDS). The clinical and immunogenetic characteristics of the patients and transplants are detailed in Table 1 . Only patients matched at second field for HLA-A, B, C, DRB1 (8/8 allele matched), verified using appropriate DNA-based methods as previously described 18 were included.
HLA-DPB1 matching status MLR or HCT pairs were divided by HLA-DPB1 type into five categories: HLA-DPB1 matched, TCE permissively HLA-DPB1 mismatched (permissive), non-permissively TCE mismatched in GvH direction (non-permissive uni-directional GvH), non-permissively TCE mismatched in HvG direction (non-permissive uni-directional HvG), and non-permissively TCE mismatched in both GvH and HvG direction (non-permissive (5) 24 (5) 34 (6) 9 (6) CsA+MTX ± other 144 (26) 426 (28) 147 (28) 139 (26) 39 (27) CsA ± other (no MTX)
11 (2) 43 (3) 11 (2) 17 (3) 
24 (4) 76 (5) 26 (5) 34 (6) 14 (10) Other 11 (2) 27 (2) 9 (2) 9 (2) 2 (1) Year of HCT 0. 23 1999-2002 146 (27) 379 (25) 117 (22) 149 (28) 40 (28) (25) 333 (22) 109 (21) 115 (22) 23
28 (5) 114 (7) 50 (9) 37 (7) 14 (10) Idipathic pneumonia syndrome 13 (2) 52 (3) 22 (4) 29 (5) 9 (6) Infection 54 (10) 142 (9) 50 (9) 53 (10) 15 (10) Organ failure 51 (9) 107 (7) 43 (8) 52 (10) 15 (10) Others 32 (6) 93 (6) 23 (4) 35 (7) 10 (7 bi-directional). Permissive or non-permissive TCE mismatches were defined according to the three-group model (TCE3) as previously described. 9 Clinical outcomes
The primary outcomes overall survival (OS), transplant-related mortality (TRM), relapse and acute GvHD were defined as previously described. 10 Relapse was considered as competing risk for TRM, and death as competing risk for acute GvHD, as defined by the CIBMTR consensus criteria.
Statistical methods
For evaluation of MLR results, statistical comparisons were performed using the unpaired t-Test, with Po0.05 as threshold for significance. All statistical analyses were performed using the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). For evaluation of clinical results, the Kruskal-Wallis and chi-square tests were used to analyze differences for discrete or continuous factors, respectively, between the five different HLA-DPB1 matching groups (matched, mismatched permissive, non-permissive uni-directional GvH or HvG or bi-directional). Kaplan-Meier probabilities were calculated for OS and estimated cumulative incidence (CI) for events with competing risks, that is, TRM, relapse and acute GvHD. Comparisons of survival curves were done with the log-rank test, and multivariate analyses using the Cox proportional hazards model, evaluating each HLA-DP matching algorithm (Figure 1 ) independently as the main effect. Models were fit to determine which risk factors were related to a given outcome. All variables were tested for affirmation of the proportional hazards assumption. Factors violating the proportional hazards assumption were adjusted through stratification. A stepwise model building procedure was used to select risk factors for each outcome with a threshold of P ⩽ 0.05 for entering the models. Due to multiple comparisons, Po0.01 was used to determine statistical significance for the main effect. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Directionality of non-permissive HLA-DPB1 TCE mismatches HLA-DPB1 alleles from the three different TCE groups were originally proposed to differ in their ability to elicit an alloreactive immune response, with descending immunogenicity from TCE group 1 to TCE group 3 (immunogenicity model; Figure 1a ). 7 Alternatively, structural diversity of HLA-DP molecules encoded by alleles from different TCE groups could lead to stronger recognition of HLA-DP alloantigens across different TCE groups compared with alleles from the same TCE group (diversity model; Figure 1b ). Non-permissive HLA-DPB1 TCE mismatches according to the immunogenicity model are exclusively uni-directional in GvH or HvG direction, due to the supposed hierarchy of immunogenicity (Table 2 ). In contrast, in the diversity model, non-permissive TCE mismatches can be bi-directional when at least one of the mismatched HLA-DPB1 alleles belongs to a TCE group not shared between donor and recipient ( Table 2) . Among the 36 possible TCE group combinations between donor-recipient HLA-DPB1 alleles, 12 are concordantly permissive or uni-directional non-permissive in both models. Sixteen other combinations are non-permissive in both models, but change from uni-to bi-directional in the immunogenicity and the diversity model, respectively. The 8 remaining combinations are permissive in the immunogenicity but non-permissive in the diversity model. These combinations require either the presence of an HLA-DPB1 allele from TCE group 1 in both donor and recipient, or homozygosity for two alleles from TCE group 2 in either donor or recipient (Table 2 ). Due to the frequency distribution of HLA-DPB1 alleles in European Whites, 19 these discordant cases are very infrequent, representing only 5/420 (1.2%) and 21/3281 (0.6%) of pairs in the MLR and clinical cohort from the present study, respectively ( Figure 2 and Table 1 ). In contrast, 124/166 (75%) and 1056/1199 (88%) of non-permissive HLA-DPB1 mismatches in the MLR and clinical cohort, respectively, were concordantly uni-directional in both models, while 42/166 (25%) and 143/1199 (12%) were uni-directional in the immunogenicity but bi-directional in the diversity model ( Figure 2 and Table 1 ).
In vitro MLR responses to HLA-DPB1 mismatches
The strength of the proliferative T-cell alloresponse to mismatched HLA-DP according to the two models was quantified by use of the 
Shown are all 36 possible combinations of TCE group assignment to the two HLA-DPB1 alleles present in patient or stimulator (S) cells and in donor or responder (R) cells. For each combination, assignment as permissive (P), non-permissive uni-directional GvH (G) or HvG (H) or bi-directional (B) is shown according to the immunogenicity model (before the hyphen) or the diversity model (after the hyphen), as shown in Figure 1 . Non-permissive assignments changing from uni-directional in the immunogenicity model to bi-directional in the diversity model are shown in bold. Permissive assignments in the immunogenicity model changing to non-permissive uni-or bi-directional in the diversity model are shown in italics. All other assignments were concordant between the two models and are shown in filled boxes.
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results obtained in the 1990's for routine MLR testing of 420 recipient-donor pairs matched for HLA-A,B,C,DRB1,DQB1 (10/10) ( Figure 2 ). Of these, 75 pairs were matched also for HLA-DPB1 (12/12) while the remaining 345 pairs were HLA-DPB1 mismatched. The 12/12 pairs showed low levels of proliferative alloresponses with a median RR of 1, suggesting that allelic differences that might have gone undetected by the HLA high resolution standards of the 1990's did not have a major impact on T-cell alloreactivity (Figure 2a ). In line with previous observations that a broad spectrum of allogeneic HLA-DP molecules is able to elicit T-cell responses, 20, 21 the permissive pairs showed significantly higher proliferative alloresponses with a median RR of 7, compared with 12/12 pairs (P o0.001; Figure 2a) . However, also in accordance with previous results, 13 proliferative responses to non-permissive mismatches were significantly higher than those to permissive mismatches, with a median RR of 17 (P o 0.001, Figure 2a ). Only 5 pairs were discordantly permissive in the immunogenicity but non-permissive in the diversity model, and showed variable MLR responses (Figure 2a) . Within the non-permissive pairs, bi-directional mismatches according to the diversity model elicited significantly higher proliferative responses (median RR = 27.5) than concordantly uni-directional mismatches in both models, either in the GvH (median RR = 15.5) or the HvG (median RR = 7) vector (Figure 2b) . Similar results were obtained in independent MLRs set up in both directions, i.e. using irradiated patient PBMC as stimulators and donor PBMC as responders (Figure 2 ), or vice versa (data not shown).
Clinical study population and outcomes The population included 3281 clinical study patients who received HCT from an HLA-A,B,C,DRB1 (8/8) matched UD for treatment of acute leukemia or MDS. 10 Five hundred forty five (16.6%) donors were also matched for HLA-DPB1, while the remaining 2736 (83.4%) were mismatched. Within the latter, 1537 (56.2%) were permissive, while 1199 (43.8%) were non-permissive, and of these, 527 (44.0%), 529 (44.1%) and 143 (11.9%) were non-permissive GvH, HvG or bi-directional, respectively. All clinical characteristics were well balanced across the groups ( Table 1) .
The overall incidence of the four major clinical endpoints of this study were OS 40% at 5 years, TRM 32% at 5 years, severe acute GvHD grade III-IV 18% at 100 days, and relapse 32% at 5 years with a median follow-up time of 61 months.
Clinical risk associations of non-permissive HLA-DPB1 TCE mismatches according to directionality In accordance with previous data, 9, [22] [23] [24] . The latter were divided into concordantly TCE permissive in both models (N = 179), concordantly non-permissive in both models (N = 161), or discordantly permissive in the immunogenicity but non-permissive in the diversity model (N = 5). The median RR was significantly lower in HLA-DPB1 matched (RR = 1) compared with mismatched MLR; however within the latter, the median RR was significantly higher against concordantly non-permissive (RR = 17) compared with concordantly permissive (RR = 7) TCE mismatches (Po 0.001). The median RR of the five discordant pairs was 1. (b) Median RR in the HLA-DPB1 non-permissive pairs, either uni-directional in GvH (N = 58) or in HvG (N = 66) direction, or bi-directional (N = 42). The median RR in uni-directional GvH (RR = 15.5) or HvG (RR = 7.5) pairs was not significantly different, while it was significantly higher in bi-directional pairs (RR = 27.5; Po0.0001). Table 3 . Multivariate regression models for association between non-permissive HLA-DPB1 uni-or bi-directional mismatches and clinical outcome
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value Adjusted for disease, disease status, graft type, GvHD prophylaxis, year of transplant, recipient race, Karnofsky performance score, CMV match status, ABO match, use of TBI and recipient age at transplant. reduced risks of acute GvHD (HR 0.71, 95% CI 0.54-0.94, P = 0.01) ( Table 3) . Also in line with previous reports, [7] [8] [9] [10] 24 non-permissive HLA-DPB1 mismatches were associated with significantly higher risks of mortality compared with permissive mismatches, both overall (HR 1.15, 95% CI 1.04-1.27, P = 0.005) and transplantrelated (HR 1.30, 95% CI 1.14-1.49, P o 0.0001) ( Table 3 ). This effect was evenly distributed throughout bi-directional and uni-directional GvH or HvG mismatches, with similar HR for these two endpoints compared with permissive mismatches. These were statistically significant for uni-directional GvH and HvG mismatches for TRM (HR 1.28, 95% CI 1.08-1.53, P o 0.0049 and HR 1.32, 95% CI 1.11-1.57, Po 0.0013, respectively), and for uni-directional HvG mismatches for OS (HR 1.18, 95% CI 1.04-1.34, P o0.0091) ( Table 3 ). Adjusted CI of TRM was significantly different between the non-permissive group (both bi-directional and uni-directional GvH or HvG mismatches) and the permissive or HLA-DPB1 matched group (P = 0.0013, Figure 3 ). In line with previous observations, 10 no significant differences were seen for the endpoints relapse and acute GvHD, although there was a trend for lower relapse risk associated with uni-directional GvH mismatches (HR 0.86, 95% CI 0.70-1.04, P = 0.12, Table 3), as previously described. 9, 24 
DISCUSSION
The data from this study do not support a significant role of directionality in non-permissive HLA-DPB1 TCE mismatches for clinical risk associations after UD HCT. In particular, bi-directional and uni-directional mismatches had similar hazards for the four major clinical endpoints OS, TRM, relapse and acute GvHD. It should be noted that bi-directional mismatches represented only 11.9% of non-permissive mismatches in the clinical study cohort overall, thereby limiting statistical power and possibly explaining the failure to find statistically significant risk associations in comparison to permissive mismatches in this subgroup. However, the striking similarities in hazard values between bi-directional and uni-directional mismatches for all study endpoints strongly suggests similar risk associations of these subgroups. Interestingly, we confirm previous observations from independent study cohorts 9, 24 of reduced relapse risk associated with non-permissive uni-directional GvH but not HvG or bi-directional mismatches, which was not accompanied by a similar increase in the hazards of acute GvHD, resulting in the worst overall mortality risks for the HvG mismatches. This finding is concordant with a relevant role of HLA-DPB1 as GvL target, as described in different clinical and experimental studies including a most recent report suggesting that T cells alloreactive to HLA-DPB1 might be exploited for specific leukemia immunotherapy in the context of allogeneic HCT. 22, 25, 26 In a previous report in unrelated UCB HCT, uni-directional HvG mismatches at HLA-A, B, C, DRB1 were associated with slower engraftment, higher graft failure and higher relapse rates compared with GvH mismatches, 5 although this was not confirmed in another report. 27 In contrast, in 7/8 matched UD HCT, HvG mismatches at HLA-A, B, C, DRB1 were found to be associated with better outcomes than GvH or bi-directional mismatches. 4 This might reflect intrinsic differences in the effect of mismatches at HLA loci other than HLA-DPB1, as well as the particularity of the TCE model which takes into account differential alloreactive potential of certain allele mismatch combinations.
Recently, the model of non-permissive HLA-DPB1 TCE mismatches was further refined by considering the delta between numerical functional distance scores assigned to HLA-DPB1 alleles in recipient and donor on the basis of the median impact of amino acid polymorphism on T-cell alloreactivity (ΔFD). 28 This refined model which has 80% overlap with the original TCE algorithm does not have a direction because the difference is always a positive number. The significant risk associations observed between high ΔFD values and OS and TRM 28 are therefore in concordance with the findings from the present study suggesting limited impact of directionality on the TCE model.
The TCE model has also been shown to have a high degree of overlap with a more recent model of HLA-DPB1 matching which considers HLA-DP expression levels governed by the single nucleotide polymorphism (SNP) rs9277534 in the 3 0 untranslated region. 29 Mismatches involving HLA-DPB1 alleles with the high expression rs9277534 variant in the patient were associated with significantly higher risks of acute GvHD compared with others. The rs9277534 SNP is in tight linkage disequilibrium with HLA-DPB1 alleles, with the high and low expression variant associated with the most frequent alleles from TCE groups 1/2 and TCE group 3, respectively, although some exceptions do occur. 29, 30 Due to these associations, the TCE model and the expression model of HLA-DPB1 mismatches have a marked degree of overlap, 29, 30 suggesting that they might be surrogates for each other or, alternatively, synergize with each other. The data from this report do not argue for or against either of these hypotheses. Further independent studies are warranted to better clarify this important point.
The study of bi-directional vs uni-directional mismatches was also aimed at obtaining further evidence for the basis of HLA-DPB1 TCE groups, which could reflect intrinsically differential immunogenicity, structural diversity, or both. The observation that in vitro proliferative responses in one-way MLR were significantly higher in the presence of bi-directional compared with uni-directional GvH or HvG non-permissive HLA-DPB1 mismatches is compatible with the diversity model. Of note, proliferative alloresponses in one-way MLR were not significantly different between non-permissive uni-directional mismatches in GvH or HvG direction. For the latter, this might reflect the ability of irradiated stimulator cells to affect responder T-cell proliferation possibly by the release of cytokines in response to allogeneic MHC on the responder cells (HvG). From the clinical side, this finding is consistent with the observation that non-permissive uni-directional GvH or HvG donor-recipient HLA-DPB1 mismatches were consistently found to be associated with similar hazards of acute GvHD and mortality after UD HCT both in the present and in previous studies. 9, 10 The data reported here are also compatible with previous results obtained on a more limited series of 24 MLR, 13 showing that the in vitro T-cell alloresponse to HLA-DPB1 mismatches is significantly higher in the non-permissive compared with the permissive context. Nevertheless, the lack of parallelism between the proliferative response to bi-directional non-permissive HLA-DPB1 mismatches and clinical risk associations found in the present study also suggest that functional in vitro data, especially if obtained from non-transplanted individuals, do not always adequately reflect clinical risk prediction, as previously shown by others. 31, 32 In conclusion, the data from the present study suggest that clinical risk stratification by non-permissive TCE mismatches is not improved by considering the directionality of mismatches, in particular bi-directional mismatches. These findings will be useful for the application of the TCE matching in UD searches. [14] [15] [16] 
